Biogen stock plunges more than 30% after a Food and Drug Administration panel committee rules against giving the company's Alzheimer's drug the nod.
Biogen Alzheimer's drug closer to approval
Biogen has shown "exceptionally persuasive" evidence that its experimental Alzheimer's disease drug is effective, U.S. Food and..
Reuters Studio